Document is current
Any future updates will be listed below
-
Authors
Kochenova, Olga V.
D’Alessandro, Giuseppina https://orcid.org/0000-0001-5448-8652
Pilger, Domenic https://orcid.org/0000-0001-7339-0685
Schmid, Ernst https://orcid.org/0000-0002-4662-5298
Richards, Sean L.
Garcia, Marcos Rios
Jhujh, Satpal S. https://orcid.org/0000-0001-5766-659X
Voigt, Andrea
Gupta, Vipul
Carnie, Christopher J. https://orcid.org/0000-0001-7006-5596
Alex Wu, R.
Gueorguieva, Nadia
Lam, Simon https://orcid.org/0000-0002-4476-0971
Stewart, Grant S. https://orcid.org/0000-0002-0960-3241
Walter, Johannes C. https://orcid.org/0000-0002-4186-7570
Jackson, Stephen P. https://orcid.org/0000-0001-9317-7937
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL098316)
Howard Hughes Medical Institute
Cancer Research UK (DRCPGM\100005, A:29580, C17183/A23303)
- License Information
-
More Information
Article History
Received: 30 August 2024
Accepted: 13 May 2025
First Online: 18 June 2025
Competing interests
: J.C.W. is a co-founder of MOMA Therapeutics, in which he has a financial interest. S.P.J. is Chief Research Officer (part-time) at Insmed Innovation UK, Ltd. and founding partner of Ahren Innovation Capital LLP. He is a board member of Mission Therapeutics Ltd. and is a consultant and shareholder of Inflex Ltd. The remaining authors declare no competing interests.
